Business
Resverlogix Announces Overnight Marketed Equity Offering
Resverlogix Announces Overnight Marketed Equity Offering Canada NewsWire CALGARY...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix Announces Overnight Marketed Equity Offering\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY, June 8, 2017\n\n\n\n/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/\n\n\n\nCALGARY, June 8, 2017 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX:RVX) today announced that it will undertake an overnight marketed offering of units, comprised of common shares and common share purchase warrants. The offering is being led by Bloom Burton Securities Inc. on a best efforts agency basis. The offering is to be effected in each of the Canadian provinces, other than Quebec, by way of a prospectus supplement to Resverlogix's base shelf prospectus dated October 1, 2015. Prior to the completion of the offering, Resverlogix has 105,701,543 common shares issued and outstanding. The number of units to be distributed, the price of each unit and the exercise price and term of each whole common share purchase warrant will be determined in context of the market.\n\nThis transaction is subject to satisfaction of customary closing conditions, including the receipt of all necessary regulatory and stock exchange approvals. \n\nThe securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the \"U.S. Securities Act\"), or any state securities laws, and accordingly, may not be offered or sold to, or for the account or benefit of, persons in the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act), except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the Company's securities to, or for the account or benefit of, persons in the United States or U.S. Persons.\n\nAbout Resverlogix\n\nResverlogix is developing apabetalone (RVX-208)...